Dermatological adverse events associated with use of oral mechanistic target of rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex.

Pithadia, D J; Treichel, A M; Jones, A M; Julien-Williams, P; Machado, T; Moss, J; Darling, T N

Pithadia, D J; Treichel, A M; Jones, A M; Julien-Williams, P; Machado, T; Moss, J; Darling, T N.

Afiliação

Pithadia DJ; Department of Dermatology, Uniformed Services University, Bethesda, MD, USA.
Treichel AM; Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Jones AM; Department of Dermatology, Uniformed Services University, Bethesda, MD, USA.
Julien-Williams P; Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Machado T; Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Moss J; Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Darling TN; Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Br J Dermatol ; 183(3): 588-589, 2020 09.

Article em En | MEDLINE | ID: mdl-32282933

Assuntos

Esclerose Tuberosa; Estudos de Coortes; Humanos; Alvo Mecanístico do Complexo 1 de Rapamicina; Sirolimo/efeitos adversos; Serina-Treonina Quinases TOR; Esclerose Tuberosa/tratamento farmacológico; Proteína 2 do Complexo Esclerose Tuberosa

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Tuberosa Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Br J Dermatol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google